Salix Pharmaceuticals Previews American College Of Gastroenterology 2012

Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) today announced that educational activities and numerous presentations describing the investigation of several of the Company’s products – including XIFAXAN ^® 550mg/rifaximin, APRISO ^® _, MOVIPREP ^® and SOLESTA ^® - will occur during the American College of Gastroenterology (ACG) 2012 Annual Scientific Meeting. ACG 2012 is being held in Las Vegas, NV, October 19-24, 2012.

XIFAXAN ^® 550mg/Rifaximin-Related Presentations

Hepatic Encephalopathy

Poster #926: Neff et al. “Outcomes in length of hospital stay in cirrhotics admitted for

overt hepatic encephalopathy”

Poster #927: Neff et al. “Long term survival following overt hepatic encephalopathy”

Poster #1348: Neff et al. “Malnutrition in cirrhotics; daily calorie counts and nutritional

deficits uncovered”

Poster #P1349: Neff et al. “Readmission rates and maintenance of overt hepatic

encephalopathy”

Other

Poster #P1571: Lembo et al. “Responsiveness of a tri-component endpoint in non-

constipation irritable bowel syndrome: pooled results from two phase 3 trials, TARGET 1

and TARGET 2”

Poster #P856: Kim et al. “The effect of rifaximin on staphylococcus species in the

stool”

Poster #P1486: Vizuete et al. “Rifaximin for the treatment of weight loss”

APRISO ^® -Related Presentation

President’s Plenary Session Oral Presentation: Aron et al. “Mesalamine granules

1500 mg once daily for 12 weeks provides adequate relief of IBS symptoms in irritable

bowel syndrome with diarrhea: results from a phase 2 trial”

MOVIPREP ^® -Related Presentation

Plenary Session Oral Presentation: Matro et al. “The incidence of hyponatremia with

two commonly prescribed purgatives for colonoscopy – polyethylene glycol 3350 with

sports drink (PEG-SD) compared to polyethylene glycol with electrolyte solution (PEG-ELS)”

About XIFAXAN ^® (rifaximin) 550 mg tablets

Important Safety Information

XIFAXAN 550 mg is indicated for reduction in risk of overt hepatic encephalopathy (HE) recurrence in patients ≥ 18 years of age. In the trials of XIFAXAN for HE, 91 percent of the patients were using lactulose concomitantly. XIFAXAN has not been studied in patients with MELD scores greater than 25, and only 8.6 percent of patients in the controlled trial had MELD scores over 19. There is increased systemic exposure in patients with more severe hepatic dysfunction. Therefore, caution should be exercised when administering XIFAXAN to patients with severe hepatic impairment (Child-Pugh C).

1 2 3 4 Next › Last »